Biotech | April 03, 2026
Nearly 40 industry groups unite to push for EU Biotech Act II
A joint position paper warns that Europe is the only major global region without a dedicated biomanufacturing initiative
A joint position paper warns that Europe is the only major global region without a dedicated biomanufacturing initiative
Government outlines advanced shared infrastructure and DBT-ICGEB biofoundry expansion to fast-track lab-to-market innovation across six strategic biotech sectors
Empowering 15 Women in STEM (Life Sciences) with scholarship, internship and mentorship
The price revision, effective April 3, 2026, brings the innovator molecule within the reach of a significantly larger patient base across the country
The company has achieved a turnover of around Rs 100 crore in FY 2025–26 and aims to achieve a turnover of Rs 500 crore in next three years
Eylea 2mg (intravitreal aflibercept injection) is an anti-VEGF therapy that blocks a protein responsible for abnormal blood vessel growth and leakage in the retina
The move represents a significant milestone in Lupin’s strategy to expand its specialty care portfolio and strengthen its presence in Europe
The company’s broader OX2R portfolio includes clinical and preclinical assets with potential applications across neurological, neurodegenerative, and neuropsychiatric conditions
The FDA approval makes PD-L1 IHC 22C3 pharmDx the only companion diagnostic approved to detect tumors expressing PD-L1 in esophageal or GEJ carcinoma patients for KEYTRUDA treatmen
The SCOUT-HCM trial hit its primary endpoint, showing a clinically meaningful and statistically significant reduction in Valsalva left ventricular outflow tract
Subscribe To Our Newsletter & Stay Updated
